Second Alzheimer’s drug in pipeline can slow the disease by a few months but with safety risk
New research shows another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening
Alzheimer’s drug
Alzheimer’s drug Leqembi has full FDA approval now and that means Medicare will pay for it
U.S. officials have granted full approval to a closely watched Alzheimer’s drug for patients with early stages of the disease
